YKL-40, a glycoprotein involved in cell differentiation, has been associated with neurodevelopmental disorders, angiogenesis, neuroinflammation and glioblastomas. We evaluated YKL-40 protein distribution in the early human forebrain using double-labeling immunofluorescence and immunohistochemistry. Immunoreactivity was detected in neuroepithelial cells, radial glial end feet, leptomeningeal cells and choroid plexus epithelial cells. The subpial marginal zone was YKL-40-positive, particularly in the hippocampus, from an early beginning stage in its development. Blood vessels in the intermediate and subventricular zones showed specific YKL-40 reactivity confined to pericytes. Furthermore, a population of YKL-40positive, small, rounded cells was identified in the ventricular and subventricular zones. Real-time quantitative RT-PCR analysis showed strong YKL-40 mRNA expression in the leptomeninges and the choroid plexuses, and weaker expression in the telencephalic wall. Immunohistochemistry revealed a differential distribution of YKL-40 across the zones of the developing telencephalic wall. We show that YKL-40 is associated with sites of the brain barrier systems and propose that it is involved in controlling local angiogenesis and access of peripheral cells to the forebrain via secretion from leptomeningeal cells, choroid plexus epithelium and pericytes. Furthermore, we suggest that the small, rounded, YKL-40positive cells represent a subpopulation of astroglial progenitors, and that YKL-40 could be involved in the differentiation of a particular astrocytic lineage. (J Histochem Cytochem 62:369-388, 2014) 
Introduction
YKL-40, also named chitinase 3-like 1 (CHI3L1), a member of mammalian chitinase-like proteins, is a heparin-, chitinand collagen-binding glycoprotein without chitinase activity (Hakala et al. 1993; Bigg et al. 2006) . The interleukin receptor, IL-13Rα2, was recently identified as a receptor for YKL-40, but other receptors may also exist (He et al. 2013) . YKL-40 is a highly conserved glycoprotein mainly produced by fetal and embryonic stem cells, neutrophils, macrophages, reactive astrocytes and cancer cells (Rehli et al. 1997; Volck et al. 1998; Junker et al. 2005; Johansen et al. 2009; Horbinski et al. 2010; Brøchner et al. 2012) . YKL-40 stimulates the production of vascular endothelial growth factor (VEGF), and plays a role in angiogenesis (Faibish 528514J HCXXX10.1369/0022155414528514Bjørnbak et al.YKL-40 Francescone et al. 2011; Shao 2013) , inflammation (Recklies et al. 2005; Lee et al. 2011 ) and cellular proliferation and differentiation (Johansen et al. 2007; Brøchner et al. 2012 ).
YKL-40, Neuroinflammation and the Brain Barrier System
Plasma YKL-40 is emerging as a new biomarker for disease severity and poor prognosis in patients with cancer and diseases characterized by inflammation and tissue remodeling (Johansen et al. 2009; Johansen et al. 2010; Kjaergaard et al. 2010) . YKL-40 is increased in the cerebrospinal fluid of patients with multiple sclerosis (MS) (Bonneh-Barkay et al. 2010 ) and purulent meningitis (Østergaard et al. 2002) . In vivo, YKL-40 transcription in the brain is associated with astrocytes in MS and simian immunodeficiency virus encephalitis (SIVE; pigtailed macaque) and possibly also with Alzheimer's disease, amytrophic lateral sclerosis, autism, Pick's disease and schizophrenia (Chung et al. 2003; Colton et al. 2006; Garbett et al. 2008; Bonneh-Barkay et al. 2010) . Bonneh-Barkay et al. also propose that YKL-40 is correlated with reactive gliosis, particularly in response to neuroinflammation Bonneh- Barkay et al. 2010) . Accumulated work in the field suggests that neuroinflammation is of great importance in almost all neurological disorders, and that interactions between the brain barriers and the immune system contribute to this process (Stolp et al. 2013) .
In a study of YKL-40 expression in developing human embryonic and fetal tissues, YKL-40 was found to be associated with tissues undergoing morphogenetic changes (Johansen et al. 2007 ). We showed unique mRNA expression of YKL-40 in the human fetal choroid plexus (Johansen et al. 2007 ), a prominent part of the brain barrier system involved in the process of neuroinflammation (Stolp et al. 2013) . The distribution of YKL-40 in the developing human forebrain and its possible role in brain barrier sites is unknown.
YKL-40, Glioblastomas and Neural Stem Cells
YKL-40 plasma levels are elevated in 55-75% of patients with glioblastoma as compared with healthy subjects (Hormigo et al. 2006; Iwamoto et al. 2011; Bernadi et al. 2012) . Following surgery for glioblastoma and anaplastic glioma, plasma levels of YKL-40 are lower in patients with no radiographic evidence of disease as compared with patients with radiographic evidence, and results suggest that increases in YKL-40 plasma concentrations during the follow-up are associated with shorter survival times (Iwamoto et al. 2011) . Microarray gene analyses have shown that YKL-40 is overexpressed in glioblastoma multiforme, as compared with normal tissue (Lal et al. 1999; Markert et al. 2001; Tanwar et al. 2002; Shostak et al. 2003; Nigro et al. 2005; Ku et al. 2011) . Tumor stem cells may be involved in the initiation of gliomas and bear a resemblance to neural stem cells (Schiffer et al. 2010) , which are present during the early development of the brain. In an earlier study, we have found a differential expression of YKL-40 in human embryonic stem cells and in cell progeny of the three germ layers, including the neuroectoderm (Brøchner et al. 2012) . Given the association between YKL-40 and glioblastoma, YKL-40 is an intriguing possible marker of human neural stem cells or their progenitors.
YKL-40 in the Early Developing Human Forebrain
Studying the complex development of the human fetal cerebral cortex is impeded by obvious difficulties-for example, applying cell fate mapping-and therefore lags behind studies of nonhuman mammals (Bystron et al. 2008; Howard et al. 2008) . Extrapolating directly from rodents to humans is not without risk, as human neocortical complexity far exceeds that of rodents. Hence, findings based on human samples are very important in order to understand normal brain development and disorders of the central nervous system. So far, YKL-40 has been described particularly in diverse pathological conditions and promoted as a factor with profound implications for both diagnostic and therapeutic applications (Prakash et al. 2013) , whereas the general role of YKL-40 in developmental biology has been largely ignored, with a few exceptions (Johansen et al. 2007; Brøchner et al. 2012) . In order to elucidate its possible functions during brain development, we have focused on YKL-40 protein and its mRNA expression in human embryonic and fetal forebrain. Using immunohistochemical, double-labeling immunofluorescence and mRNA analysis, we describe the spatiotemporal appearance and distribution of YKL-40 in human forebrain from the 6 th to the 21 st week post-conception (wpc).
Materials & Methods

Tissue Samples
Nine human embryos (6 th week, n=2; 7 th , n=2; 8 th , n=5) and 35 fetuses (9 th week, n=3; 10 th , n=2; 11 th , n=3; 12 th , n=3; 13 th n=2; 14 th , n=6; 15 th , n=4; 16 th , n=4; 17 th , n=2; 18 th , n=2; 19 th , n=1; 20 th , n=1; 21 st , n=2) were examined immunohistochemically. Two human embryos (7 th week, n=1; 8 th , n=1) and three human fetuses (9 th week, n=2; 10 th , n=1) were used for real-time quantitative RT-PCR analysis. The embryos and fetuses ranged from 7 to 200 mm in crownrump length (CRL), corresponding to 6 th -21 st wpc. The samples were obtained either from the archives of the human embryonic/fetal biobank, Department of Cellular and Molecular Medicine at the University of Copenhagen or from legal abortions. According to the Helsinki declaration II, oral and written information was given and informed consent was obtained from all contributing women, according to and approved by the Research Ethics Committee of the Capital Region (KF-V.100.1735/90).
Immediately following surgery, the samples were either dissected into blocks and fixed for 12-24 hr at 4C in either 10% neutral-buffered formalin, 4% Formol-Calcium, Lillie's or Bouin's fixatives or, alternatively, carefully isolated and stored in RNAlater for subsequent PCR analysis. The specimens intended for immunohistochemistry were dehydrated with graded alcohols, cleared in xylene, and embedded in paraffin. Serial sections, 3-10-µm thick, were cut in transverse, sagittal or horizontal planes and placed on silanized glass slides.
Immunohistochemistry
Sections were deparaffinized and rehydrated in xylene followed by a series of graded alcohols, treated with a 0.5% solution of hydrogen peroxide in methanol for 15 min to quench endogenous peroxidase, and then rinsed in Trisbuffered saline (TBS, 5 mM Tris-HCl, 146 mM NaCl, pH 7.6). Non-specific binding was inhibited by incubation for 30 min with blocking buffer (ChemMate antibody diluent S2022; DakoCytomation, Glostrup, Denmark) at room temperature. The sections were incubated overnight at 4C with a mouse monoclonal antibody against human YKL-40 (201. F9, IgG2bκ, epitope GAWRGTTGHHS corresponding to amino acids 210-220 at a 1:50-1:100 dilution of the 1.9 mg/ ml stock concentration in blocking buffer (ChemMate antibody diluent S2022)). The sections were washed with TBS and incubated for 30 min with a peroxidase-labeled polymer conjugated to goat anti-mouse immunoglobulins (DAKO EnVision TM + System/HRP K4007, DakoCytomation). The sections were washed with TBS and incubated for 10 min with 3,3'-diamino-benzidine chromogen solution. Positive staining was recognized as brown staining. The sections were counterstained with Mayer's hematoxylin and dehydrated in graded alcohols followed by xylene and coverslipped with DPX mounting media. Staining specificity was tested by preincubating the 201.F9 monoclonal antibody with purified human YKL-40 for 2 hr at room temperature or overnight at 4C to block YKL-40 binding sites and reveal possible nonspecific staining to the sections. The preabsorbed sections showed a lack of or a diminished reactivity ( Fig. 1) , which is in accordance with previously described results (see Figure 1 in Johansen et al. 2007 ). Positive controls included staining of tissue known to be immunoreactive for YKL-40 (Johansen et al. 2007 ). Non-immune mouse IgG1 (X0931, IgG1 concentration 7.5 µg/ml, DakoCytomation) was used as a negative control.
Double immunolabeling was performed with antibodies against YKL-40 and von Willebrand Factor (vWF) or YKL-40 and glial fibrillary acidic protein (GFAP). Prior to staining, nonspecific binding was inhibited by incubation for 30 min with 0.2% casein (C-7078; Sigma-Aldrich, St. Louis, MO) at room temperature. The sections were absorbed in human serum (known donor) and then incubated at 4C overnight with a mixture of antibodies against YKL-40 (201.F9, IgG2bκ, mouse, 1:100 dilution of the 1.9 mg/ml stock concentration) and vWF (A0082, rabbit, 1:1200; DakoCytomation) diluted in 0.2% casein. Following this, endogenous peroxidase was quenched using 0.3% hydrogen peroxide for 15 min. Sections were incubated for 30 min at room temperature with Labelled Polymer -HRP anti-mouse (DakoCytomation, EnVision TM + System/HRP K4007) followed by Tyramid Signal Amplification with Alexa Fluor 488 Tyramide (T20912; Invitrogen, Molecular Probes, Carlsbad, CA) for 7 min at room temperature. Subsequently, the sections were incubated for 30 min at room temperature with biotin-SP-conjugated F(ab') 2 fragment donkey anti-rabbit antibodies (711-066-152, 1:200; Jackson ImmunoResearch Laboratories, West Grove, PA) followed by streptavidin-conjugated DyLight 594 (SA5594, 1:200; Vector Laboratories, Burlingame, CA). Finally, a nuclear counterstain with DAPI (D1306, 1:1000; Invitrogen) was added for 3 min, and the sections coverslipped. For double staining with antibodies against YKL-40 and GFAP, the sections were prepared as described above, and then incubated with antibodies against YKL-40 (1:50 dilution of the 1.9 mg/ml stock concentration) overnight at 4C. After staining for YKL-40, sections were incubated with an antibody against GFAP (Z0334, rabbit, 1:700; DakoCytomation) overnight, with secondary antibody and nuclear counterstaining performed as described above.
Fluorescent imaging was performed using a Zeiss Axioplan 2 microscope, and laser scanning confocal microscopy performed using a Carl Zeiss LSM 780 with a Plan-Apochromat 63/1.40 Oil DIC M27 objective and the following lasers and emission filters: for excitation of Alexa Fluor 488, a 488 nm argon laser with an emission filter of 493-590 (green fluorescence); for excitation of DyLight 594, an In Tune laser with an emission filter of 596-692 (red fluorescence). During image acquisition, a sequential scanning procedure through the z-axis of the double-labeled sections was applied covering a total depth of 9 µm. Confocal images were taken and analyzed throughout the z-axis of the section, and individual optical sections were stored as TIFF files using Zeiss ZEN Vision v10. Representative images for figure editing were chosen from the analyzed samples.
Real-time Quantitative RT-PCR Analysis
Tissue samples for mRNA analysis were placed in RNAlater (Ambion, Austin, TX) immediately after dissection and stored according to the manufacturers' instructions. Total Note the lack of or a markedly diminished reactivity of the sections stained with the preabsorbed YKL-40 antibody. The end feet layer (EFL) is barely visible in (B) and (F), and the presumed astroglial progenitors (arrow) in the subventricular zone (SVZ) in (C) is no longer positive following preabsorption (D). Note the reactivity associated with the blood vessel in (C) (arrow) and the lack of reactivity in (D) (arrow). (G) Quantitative real-time RT-PCR analysis of YKL-40 mRNA expression in the human developing forebrain from tissue samples dissected from two human embryos (aged 6 weeks and 5 days post-conception and 7 wpc) at the 7 th and 8 th wpc and three human fetuses (aged 8 wpc, 8 weeks and 3 days post-conception, and 9 wpc) at the 9 th and 10 th wpc. Relative mRNA expression is shown (meninges=1). Only one meninges sample was available for analysis. A significant difference between average expression values obtained in the telencephalon (n=4) and the choroid plexus (n=3) RNA was isolated from the tissue sample using TRIzol Reagent (Invitrogen) and RNA quality was determined by agarose gel electrophoresis. cDNA was synthesized with SuperScript II (RNase H-) reverse transcriptase (Invitrogen) according to manufacturer's instructions. Real-time quantitative RT-PCR (QPCR) analysis was performed using an ABI 7500 Fast real-time PCR system and with a LightCyclerFastStart DNA MasterPLUS SYBR GreenI kit (Roche, Hvidovre, Denmark). All samples were analyzed in duplicates. Expression levels were determined using a standard curve, generated by 10-fold dilutions of the PCR product. Data were normalized using the average expression value of four housekeeping genes (B2M, HPRT, ATP6A and COX4A) and related to the choroid plexus at 6 weeks and 5 days post-conception, as we have shown previously a strong YKL-40 expression in developing human choroid plexus (Johansen et al. 2007 ). YKL-40 primer sequences were: 5' AATGGGTGTGAAGGCGTCT 3' and 5' GGTACAGA GGAAGCGGTCAA 3'. Primer sequences for the housekeeping genes are available upon request. Statistical analysis was performed using Student's t-test.
Results
Immunostaining for YKL-40 resulted in a clear and welldefined staining pattern, irrespective of the fixative used. Control sections, where the YKL-40 antibody was preabsorbed with YKL-40 antigen, showed a lack of or a strongly diminished reactivity at the early and late fetal ages ( Fig. 1A-1F ). QPCR was used to relate the YKL-40 distribution observed with immunohistochemistry at the protein level to its mRNA expression in the forebrains of embryos and fetuses at 7 th -10 th wpc. The telencephalic wall, meninges and choroid plexus from two human embryos at the 7 th and 8 th wpc (aged 6 weeks and 5 days post-conception and 7 wpc) and three human fetuses in 9 th and 10 th wpc (aged 8 wpc, 8 weeks and 3 days and 9 wpc) showed positive YKL-40 mRNA expression, with the strongest expression observed in the meninges (Fig. 1G ). The choroid plexus showed significantly stronger expression than that in the telencephalon (Student's t-test, p=0.029).
The distribution of YKL-40 immunoreactivity is described in relation to the important developmental features of the human forebrain, and is based on and, in some cases, normalized against, gestational weeks or CRL to estimate the approximate number of wpc. 6 th week: Early neurogenesis (Bystron et al. 2008 ) and formation of radial glial cells (RGCs) (Howard et al. 2008 ), formation of the preplate (PP) (Bystron et al. 2008 ) and hippocampal thickening (Humphrey 1966) . 7 th week: The choroid plexus of the lateral ventricles emerges (Jacobsen et al. 1982) . Reelin-producing Cajal-Retzius cells (CRCs) (Abraham et al. 2004 ) and the subventricular zone (SVZ) appear (Møllgård and Jacobsen 1984; Bystron et al. 2008 ). 8 th week: Formation of the cortical plate (CP) (Bystron et al. 2008) . 9 th to 11 th week: The intermediate zone (IZ) and subplate (SP) can be separated by different markers (Bystron et al. 2008) and microglia appear in the telencephalon (Rezaie et al. 2005) .
12 th to 14 th week: S100-positive astrocytes appear in the fimbria and hippocampus (Janas et al. 1991) , the subpial granular layer (SGL), containing CRCs, is formed (Gadisseaux et al. 1992; Meyer 2010) and the outer subventricular zone (OSVZ) can be distinguished .
15 th to 21 st week: CRCs and SGL cells descend to a deeper position within the marginal zone (MZ) (Meyer 2010) . The superficial part of the subpial glial end feet layer has not yet transformed into a subpial glia limitans, which occurs at 25 th to 28 th wpc (Kadhim et al. 1988 ).
YKL-40 Protein Distribution in 6 th to 8 th wpc Embryos
choroid plexus displayed a uniform, strong reactivity toward the end of the 8 th wpc (Fig. 2C) , and showed cytoplasmic staining in all of the distal glycogen-filled cells and a strong YKL-40 reactivity in the part of the root that is in direct continuity with the hem area and the hippocampal anlage (Fig. 2D ). The subpial layer of possible radial glial end feet became increasingly immunoreactive during the 8 th week, with the strongest reactivity corresponding to the outer surface of the hippocampal anlage and the lateral part of the dorso-lateral wall (Fig. 2C-2D ). Leptomeningeal cells in the pia-arachnoid and many of the small vessels in the meninges showed a strong YKL-40 immunostaining.
YKL-40 Protein Distribution in 9 th to 21 st wpc Fetuses 9 th to 13 th wpc: Immunoreactivity at this age corresponded to basal radial glial processes creating a subpial layer and to the ventricular lining, the choroid plexus epithelium and the leptomeninges. As in the embryos, the VZ corresponding to the cortico-choroid boundary was also YKL-40 positive. At 10 wpc, the YKL-40 reactive layer of radial glial end feet, which, in earlier specimens, had marked the outer surface of the hem, took a more rostral position lining the hippocampal primordium. From the 12 th wpc, there was a distinct stratification of YKL-40 immunoreactivity in the forebrain, with a strong staining of the pia-arachnoid on the outside of the telencephalic wall and of the choroid plexus inside the lateral ventricle ( Fig. 3 ). Within the telencephalic wall, the IZ was stained from the subiculum to the dorsal neocortex. This reactivity was due to multiple, small YKL-40-positive dots close to the IZ blood vessels. The lack of reactivity of the IZ of the hippocampal anlage was paralleled by a marked staining of the subpial lining of the MZ (Fig. 3) . The SVZ and VZ showed no staining at low magnification apart from the positively stained VZ covering the fimbria.
Cells within the CP, SP and inner SVZ showed no YKL-40 immunoreactivity and Iba1-positive subpopulations of cells, characterized by large ovoid cell bodies and few or no short processes (putative microglia), were not YKL-40 positive (not shown).
14 th to 21 st wpc: The strong YKL-40 immunoreactivity of the choroid plexus and leptomeninges and the lack of reactivity in the CP and SP persisted during forebrain development from 14 th to 21 st wpc. The stratified YKL-40 distribution in the telencephalic wall, seen at low magnification at earlier stages, became increasingly more distinct with further maturation. At the cellular level, there were obvious differences in the YKL-40 reactivity in the IZ (Figs. 4, 5) , the SVZ (Figs. 6, 7) , the MZ (Figs. 8, 9) , and the hippocampus ( Fig. 10) .
YKL-40 immunodistribution in the dorsal telencephalon of 15 th wpc human fetuses showed weak reactivity in the inner half of the cerebral wall, where small dots of YKL-40 immunostaining were most prominent in the IZ (Fig. 4A ), corresponding to the findings at 12 th wpc. The SVZ and VZ showed virtually no reactivity at this low magnification ( Fig. 4B) . At the cellular level, a fine granular staining was obviously associated with small blood vessels (arrows in Fig. 4C ), but whether the reaction product was associated with endothelial cells and/or pericytes could not be distinguished. GFAP-positive astrocytic end feet were not present in the IZ (not shown). Using confocal microscopy, the majority of the microvessel endothelial cells (EC) in the IZ/ OSVZ showed positive von Willebrand Factor (vWF, endothelial cell marker) immunostaining ( Fig. 5B ) but no immunoreactivity for YKL-40. However, directly adjacent to the endothelial cells were YKL-40-positive pericytes, which covered segments of the outer endothelial cell membranes (Fig. 5C ). The merged images demonstrate the absence of co-localization of vWF and YKL-40 ( Figs. 5D and 6 ).
In the ventral telencephalon, a unique population of YKL-40-positive cells appeared in the SVZ corresponding to the border of the lateral ganglionic eminence at 14 wpc. These small, rounded cells displayed dense, cytoplasmic YKL-40 immunoreactivity. This pattern was still present in frontal cortex at 20 wpc, and similar cells were found covering the entire SVZ in the visual cortex, indicating a differential spatio-temporal distribution of these YKL-40positive cells. In a few segments of the VZ, for example, in the developing frontal and visual cortices, similar strongly reactive YKL-40-positive cells were observed. These cells were different from the earlier described pericytes in terms of both morphology and staining characteristics and never showed direct contact with the endothelial cells, as demonstrated by confocal microscopy and double immunolabeling with antibodies against YKL-40 and vWF in subventricular zone of the visual cortex (Fig. 6) . The nuclei of the YKL-40-positive, rounded cells were larger than those of the pericytes. In order to elucidate whether these cells were GFAP-positive radial glial cells, sections were double immunolabeled with antibodies against YKL-40 and GFAP. Small clusters of YKL-40-immunopositive cells were closely associated with GFAP-positive radial glial fibers (RGF) and, in a few cases, co-localization was definitely observed (Fig. 7A-7D) .
The outermost part of the MZ appeared as a YKL-40immunopositive indented layer, with a staining reaction of varying intensity. As seen at earlier stages, there was a gradient of staining, with the strongest reactivity corresponding to the outer surface of the hippocampus, in particular the fimbria, and the lateral part of the dorso-lateral telencephalic wall. At the cellular level, a continuous layer of small YKL-40-reactive processes, corresponding to the end feet of radial glial cells, reached the pial surface as semicircular or triangularly stained elements (Fig. 8A) . Only a few processes in the end feet layer were positive for GFAP ( Fig. 8B) . Large Cajal-Retzius cells and the transient population of subpial granular cells were YKL-40-negative ( Fig. 8A) . Confocal microscopy using double immunolabeling with antibodies against YKL-40 and GFAP showed strong YKL-40 immunoreactivity (Fig. 8D ) but virtually no GFAP staining (Fig. 8E ) in the end feet layer (Fig. 8C) . At higher magnification, the end feet layer was characterized by distinct YKL-40 staining, which seemed to be associated with the membranes of all end feet (Fig. 9 ). There was a marked decrease in the immunoreactivity closer toward the cortical plate. The YKL-40immunostained leptomeningeal cells in the pia were closely opposed to the end feet layer, whereas endothelial cells of the microvasculature of the pia were not positive for YKL-40 (Fig. 9) .
The earlier described YKL-40-immunopositive features of the hippocampus, including the marked staining of the subpial layer of the marginal zone of subiculum, were much more pronounced at the later stages of development. Morphologically obvious astrocytes in the fimbria, a neuron-free region, showed a stronger YKL-40 immunoreactivity during the later half of the investigated time interval. Furthermore, a thin layer of YKL-40-positive cells, with several vertical and horizontal processes, separated the VZ from the future alveus ( Fig. 10A) . At the cellular level, a few YKL-40-positive pericytes were present and numerous strongly YKL-40-stained astrocyte-resembling cells formed a dense network, with many processes extending to the endothelial cells of the microvasculature in fimbria (Fig. 10B ).
Discussion
Our study demonstrates a novel characterization of YKL-40 in the developing human forebrain. We show a marked YKL-40 immunoreactivity in neuroepithelial cells, some PP cells, radial glial end feet, leptomeninges and choroid plexus epithelial cells during the early stages of development. Later developmental features include an increasing number of YKL-40-immunopositive pericytes, particularly in the IZ and SVZ, and a population of small, rounded, YKL-40-positive cells in close relation to and occasionally overlapping with GFAP-positive radial glial fibers in the SVZ. The choroid plexus and the layer of radial glial end feet and its covering pia-arachnoid membrane are strongly YKL-40-immunopositive, and the astrocyte-resembling cells observed in the developing hippocampus are strongly reactive.
We detected the synthesis of YKL-40 mRNA in the meninges, telencephalon and the choroid plexus. qRT-PCR analysis suggested stronger expression in the latter compared with that of the cerebral wall. However, this result should be interpreted with some caution because of the low number of samples available for analysis. The delicate membranous staining of the entire subpial glial end feet layer, as determined by confocal microscopy, is compatible with an uptake of YKL-40.
We suggest that YKL-40 plays a role in the developing brain barriers and that the YKL-40-positive, small, rounded cells are astroglial progenitors possibly involved in the differentiation of a particular astrocytic lineage. Furthermore, we propose that the glial progenitors, leptomeninges, choroid plexus epithelium, pericytes and, later, a subpopulation of astrocytes are the YKL-40-producing elements in the developing human forebrain. The section was stained with antibodies against YKL-40 (green) and von Willebrand Factor (vWF) (red), nuclear counterstained with DAPI (blue) and viewed using confocal microscopy. The YKL-40-immunopositive end feet layer (EFL, arrows) separates the leptomeninges and underlying marginal zone. No blood vessels penetrate the marginal zone in this section. Note the strongly immunoreactive leptomeningeal cells (LMC), some of which surround the vWF-positive endothelial cells (EC) of the vessels of the pia-arachnoid. The EFL forming the outermost part of the marginal zone shows a strong membranous reactivity, with a decreasing immunoreactivity within its deeper strata. Scale bar: 20 μm. 
The Brain Barrier System and Early Angiogenesis
In the 5 th to 6 th wpc, prior to vascularization of the forebrain anlage and choroid plexus development, a dense vascular plexus dominates the developing subarachnoid space between the inside of the differentiating membranous bones of the calvarium and the pial covering of the forebrain surface. After the penetration of the first vessels into the telencephalic wall and the appearance of the choroid plexus, the following mesenchymal/neuroectodermal interfaces comprise the initial brain barrier system: 1) The blood-brain barrier (BBB) proper across the YKL-40-immunonegative cerebral endothelial cells, surrounded by YKL-40-positive pericytes with a differential immunoreaction; 2) the blood-CSF barrier at the strongly YKL-40-positive choroid plexus epithelium;
and 3) the blood-arachnoid and pia-brain surface barriers, with strongly YKL-40-positive leptomeningeal cells and subpial radial glial end feet. In addition, within the neuroectoderm, per se, 4) there is a barrier interface between the CSF and the brain interstitial fluid at the apical neuroepithelial membrane (Saunders et al. 2008 ) lined by dense YKL-40 immunoreactivity in the early brain. An important interface in the early steps of the brain barrier development is the blood-CSF barrier (Stolp et al. 2013) where we found strong YKL-40 mRNA expression in the choroid plexus. Prominent YKL-40 staining was evident as early as 7 wpc (49 dpc) when the choroid plexus of the lateral ventricles first appears in the human embryonic brain. This is in accordance with previously described YKL-40 mRNA expression findings (Johansen et al. 2007 ). Our results suggest that YKL-40 is produced by the choroid plexus epithelium and secreted into the ventricular system.
A variety of secreted diffusible factors from fetal meninges regulate neural migration and positioning and organize the pial basement membrane, which is a critical anchor point for the radially oriented fibers of neuroepithelial stem cells (Siegenthaler and Pleasure 2011) . Signaling molecules identified so far include the chemokine SDF-1, BMP7 and the morphogen all-trans retinoic acid (atRA), which seem to be involved in the decision of neuroepithelial cells to generate neurons and intermediate progenitor cells destined for the SVZ via communications with adjacent radial glial end feet (Siegenthaler et al. 2009 ). We suggest that YKL-40 can be added to the list of secreted diffusible factors, as the meninges both show profound YKL-40 mRNA and protein expression and subpial radial glial end feet are YKL-40 immunoreactive. Thus, the pronounced YKL-40 immunoreactivity of the entire end feet layer associated with its bulging/curling membranes is best accounted for by receptor-mediated uptake of YKL-40 produced by leptomeningeal cells from the subarachnoid space.
Early in brain development, at the CSF-brain interface lining the cerebral ventricles, the cells of the neuroepithelium are linked by strap junctions (Møllgård and Saunders 1986; Møllgård et al. 1987) , which offer an effective limitation to intercellular diffusion, at least for large molecules (Fossan et al. 1985) . This barrier interface is lined by dense YKL-40 immunoreactivity apparently associated with apical neuroepithelial membranes and thus compatible with receptor-mediated uptake.
Pericytes are required for blood-brain barrier integrity during embryonic angiogenesis following an initial neural progenitor induction of endothelial cells to express bloodbrain barrier specific proteins, including tight junction molecules and specific nutrient transporters (Daneman et al. 2010) . Pericytes then strengthen the endothelial barrier during further embryogenesis by regulating tight junction structure, limiting the rate of transcytosis, and inhibiting the expression of leukocyte adhesion molecules. Only later the astrocytic processes are developed, and surround the endothelial and pericytic membranes, supporting the blood-brain barrier functionality (Daneman et al. 2010) . Establishment, maintenance and repair of the endothelial barrier depend on pericytes and astrocytes, and both cell types are linked to BBB disruption in disease (Argaw et al. 2012) . Early angiogenesis also depends on pericyte functionality, as migrating angiogenic pericytes precede and guide the endothelial cells of the growing telencephalic microvessels (Virgintino et al. 2007) .
The role of YKL-40 as an angiogenic factor has been studied by Francescone et al. (2011) in a human brain tumor cell line, and they showed that vascular endothelial growth factor (VEGF), a primary angiogenic promoter, is up-regulated by YKL-40. Further, their results showed that not transient but long-term inhibition of VEGF induced the expression of YKL-40, indicating that VEGF does not regulate YKL-40 but long-term inhibition of VEGF may induce YKL-40 as an angiogenic compensative response (angiogenic rebound), providing evidence for YKL-40 as a tumor maintaining angiogenic factor Shao 2013) . We found YKL-40-positive pericytes in the microvasculature of both pial and periventricular vessels, but the staining reaction differed between regions and stages. This indicates that YKL-40 has a function both in the BBB proper and in angiogenesis, as described earlier.
Within the telencephalic wall, YKL-40 appears associated with the developing vascular system, particularly in the portion of the vasculature that traverses the SVZ and IZ corresponding to the ascending arterial network (Vasudevan et al. 2008) .
The passage of immune cells through the brain barriers to the CNS is a complex process, but an essential aspect in neuroinflammation and of normal function, both during development (e.g., microglia, which are of myeloid origin) and later in life (reviewed by Stolp et al. 2013) . Using an in vitro BBB model, Correale and Fiol (2010) showed that YKL-40 significantly facilitates migration of peripheral blood mononuclear cells across the BBB. We propose that the observed YKL-40 expression associated with the developing brain barrier system is involved in controlling local angiogenesis and access of peripheral cells to the forebrain via YKL-40 secretion from choroid plexus epithelium, leptomeningeal cells and pericytes.
Microglia
Blood monocytes are known to enter the early human forebrain via choroid plexus and meninges to become amoeboid microglial cells (Aguzzi et al. 2013) . Early colonization is initially restricted to the IZ. A second wave of monocytes penetrates into the brain via the vascular route at about 12 wpc and remains confined to the IZ/white matter (Verney et al. 2010) . Areas known to harbor microglia are the inner SVZ, SP, lower cortical plate and restricted laminar bands at the axonal crossroads in the white matter (Rezaie et al. 2005; Verney et al. 2010; Cunningham et al. 2013) . Studies indicate that microglia do not show YKL-40 staining in vivo (Bonneh-Barkay et al. 2010; Craig-Schapiro et al. 2010 ). In the present study, cells with microglial characteristics were not YKL-40-immunopositive within telencephalic parenchyma in 10 th wpc and later fetuses, in support of the previous findings (Bonneh-Barkay et al. 2010 ).
Neuroepithelial Cells, Radial Glial Cells and Astroglial Progenitors
In the early embryonic period, the pros-and early telencephalic wall only consist of neuroepithelial cells. At the beginning of neurogenesis, neuroepithelial cells transform through asymmetric divisions into radial glial cells (RGCs) (Götz and Huttner 2005; Howard et al. 2008) . Ovoid RGC nuclei are situated in the VZ and SVZ of the developing neocortex and in the VZ of the hippocampus. The basal end feet of these bipolar cells face the pial surface of the fetal cerebrum (Bystron et al. 2008; Howard et al. 2008) , and shorter apical processes form the ventricular surface (Pinto and Götz 2007; Howard et al. 2008) . The RGCs may be regarded as neural stem cells. In the neocortex, the majority of RGCs initially generate neurons, which migrate along the radial glial fibers to their final destination in the cortex and, as corticogenesis progresses, they concurrently give rise to glial lineages (Malatesta et al. 2000; Pinto and Götz 2007) . In the adult subependymal zone and subgranular zone (in rodents), a population of neural stem cells with astrocyte-like morphology and marker expression persists as descendants of RGCs (Alvarez-Buylla et al. 2002; Bonfanti and Peretto 2007; Howard et al. 2008) . Recent studies have shown that astrocytes are heterogeneous in developmental origin, genetic profiling and function both in normal development and disease (Zhang and Barres 2010; García-Marqués and López-Mascaraque 2013) . A very recent analysis of the clonal dispersion of astrocytes in the mouse cerebral cortex indicates that heterogeneous astroglial populations arise from specialized progenitor cells (García-Marqués and López-Mascaraque 2013).
In this study, the neuroepithelium of 6 th wpc embryos was YKL-40-positive with cytoplasmic staining and demonstrated a gradient with a strong reactivity confined to the midline corresponding to the distribution of a subset of SSEA (stage-specific embryonic antige)4-positive neuroepithelial and early radial glial cells; this was also shown previously in the same material (Barraud et al. 2007) . Although subtle, the cytoplasmic YKL-40 staining spanned the entire VZ, with processes into the PP and increased reactivity in the outermost part of the PP, suggesting that YKL-40 is expressed by neuroepithelial cells/radial glial cells (neural stem cells) in the early VZ. At later stages, radial glial cells of the VZ were not YKL-40immunopositive, though we consistently found YKL-40 reactivity in possible RGC end feet, as described earlier. A proof of whether the neuroepithelium of the forebrain wall, including some morphogenetic centers, synthesizes or takes up YKL-40 will require in situ hybridization studies and a demonstration of a receptor for YKL-40.
We observed strongly YKL-40-positive PP cells prior to the appearance of the cortical plate. This could be due to uptake via apical PP cell processes, which terminate on the pia-arachnoid membrane, the cellular elements of which showed marked YKL-40 mRNA and protein expression. No cellular elements corresponding to the cortical plate, reelinproducing Cajal-Retzius cells in the MZ (Abraham et al. 2004 ), or to GABAergic inhibitory interneurons migrating tangentially primarily within the SVZ (Hansen et al. 2013) showed YKL-40 immunoreactivity either in 7 th week or later. The development of the subpial granular layer in 12 th -14 th wpc (Gadisseaux et al. 1992) was not reflected by a parallel appearance of numerous small YKL-40-positive cells in the MZ. From 14 wpc, we found a population of small, rounded, strongly YKL-40-positive cells in the SVZ with a differential spatio-temporal distribution. At 20 wpc, these cells were closely aligned to GFAP-positive radial glial fibers and, in a few cases, co-expression was evident, indicating that a fraction of GFAP-positive RGCs are YKL-40-immunoreactive whereas a larger subset migrate along the RGF in the SVZ.
Based on our findings of YKL-40-positive astrocyteresembling cells in the developing fimbria, a neuron-free region and lack of YKL-40 reactivity in neuron forming regions mentioned above, we suggest that the YKL-40positive cells in the SVZ represent a subpopulation of astroglial progenitors. As earlier described, YKL-40 reactivity is observed in relation to the brain barrier system, e.g., in RGC end feet, but we do not yet know if the possible astroglial progenitors described in this paper are more specifically involved in a general barrier function. Whether these cells contribute to the population of adult human neural stem cells in the subependymal zone is unknown. Further on-going studies are necessary to characterize this intriguing population of YKL-40-positive cells and confirm their lineage potential.
Clinical Aspects
Due to the presence of the brain barrier system and the muted inflammatory response within the brain parenchyma, the brain has been considered to be an immune privileged site. However, it is now suggested that neuroinflammation plays an important role in almost all neurological disorders and that the brain barrier system can contribute to this through either normal immune signaling and a maintained capacity for immune-surveillance of the brain, or via disruption of various structural and functional components of the barrier system (for recent review, see Stolp et al. 2013) . Inflammation-induced changes in the brain barrier system during development may contribute to serious developmental disorders, or change the susceptibility of the brain to later onset conditions, such as schizophrenia and neurodegenerative disease (Stolp et al. 2013) . A role of YKL-40 in inflammation and immune responses could be explained by a general YKL-40-related participation in barrier function.
Glioblastoma multiforme is a common, heterogeneous and very aggressive malignant primary brain tumor. The origin of glioblastomas is still not fully grasped, but studies imply that a minor population of cancer stem cells maintain and may initiate the tumor (Singh et al. 2003; Park and Rich 2009; Schiffer et al. 2010) . YKL-40 mRNA and YKL-40 protein expression are higher in glioblastoma than in astrocytic and oligodendroglial tumors, increase with glioma grade and high YKL-40 expression is associated with poor response to radiation and short time to disease progression and death (Pelloski et al. 2005; Colin et al. 2006; Rousseau et al. 2006; Iwamoto et al. 2011 ). Rousseau and co-workers (2006) found YKL-40 immunoreactive blood vessels in glioma tissue and YKL-40-expressing tumor cells were preferentially located in the close vicinity of blood vessels. They speculate that the increasing YKL-40 expression between low to high grade astrocytomas supports the involvement of YKL-40 in angiogenesis (Rousseau et al. 2006) . The YKL-40-positive astroglial progenitor cells, together with previously described local YKL-40 secreting pericytes found in this study, form a new interesting possible background for glioblastomas.
In summary, our results suggest that the prominent YKL-40 expression, which is associated with the brain barrier system in the developing human brain, is involved in controlling access of peripheral cells to the forebrain and a segmental CNS angiogenesis via YKL-40 secretion from pericytes, choroid plexus epithelium and leptomeninges. Furthermore, YKL-40 immunoreactivity is present in a subpopulation of possible astroglial progenitor cells migrating along radial glial fibers in the SVZ. We suggest that YKL-40 could be involved in their switch into a particular astrocytic lineage. Future on-going studies are necessary to confirm their lineage potential and their possible role in glioblastomas and to elucidate the contribution of YKL-40 to a general barrier function involved in neuroinflammation.
